Meeting Objectives:
- Provide an overview of the current viral hepatitis situation in Europe, in relation to the renewed WHO global health sector strategies 2022-2030
- Discuss initiatives, achievements, best practices and challenges from international organizations in the prevention and control of viral hepatitis
- Assess the needs to achieve elimination of viral hepatitis as a major public health threat by 2030 as set out in the new WHO Global Health Sector Strategies 2022-2030
- Investigate potential collaborations
- Discuss successes, good practices, issues and barriers to overcome and the way forward.
Background document (PDF, 702 kB)
Wednesday 5 April 2023 – Part 1
Introduction
| Chairs: Pierre Van Damme and Angela Dominguez | |
| 09:00-09:30 | Welcome and opening of the meetingWelcome and opening Introduction of the participants |
Session 1.1: WHO elimination goals – setting the scene
| 09:30-09:50 | History of Global and European efforts to control Hepatitis B (pdf, 0.651Mb)Mark Kane |
| 09:50-10:10 | Current situation & the new WHO Global Health Sector Strategies 2022-2030 (pdf, 5.737 Mb)Philippa Easterbrook, WHO HQ (ONLINE) |
| 10:10-10:30 | How to apply the WHO Global Health Sector Strategies in Europe? (pdf, 2.657 Mb)Marcelo Naveira, WHO Euro |
| 10:30-10:40 | Q&A and identify most important barriers |
COFFEE BREAK 10:40-11:10
Session 1.2: Major barriers to overcome
| Chairs: Vladimir Chulanov and Silvia Bino | |
| 11:10-11:30 | ETAGE Working Group on Hepatitis B and progress of countries of the WHO European Region towards validation of hepatitis B control targets (pdf, 1.642 Mb)Sandra Dudareva |
| 11:30-11:40 | Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C? (2020) (pdf, 1.048 Mb)Graham Cooke |
| 11:40-12:00 | Survey results on the progress toward the WHO viral hepatitis elimination goals (pdf, 1.230 Mb)Kate Turpie |
| 12:00-12:10 | Q&A and barriers to add |
Session 1.3: Role of international organisations (Part 1)
| 12:10-12:50 | European Centre for Disease Prevention and Control (ECDC) (pdf, 1.994 Mb)Erika Duffell, ECDCCenters for Disease Control and Prevention (CDC) (pdf, 1.145 Mb)Senad Handanagic, CDC (ONLINE) |
| 12:50-13:00 | Q&A and barriers to add |
LUNCH BREAK 13:00-14:00
Session 1.4: Role of International organisations (part 2)
| Chairs: Maria Buti and Daniel Lavanchy | |
| 14:00-14:30 | International Viral Hepatitis Elimination Meeting (IVEM) & The Task Force for Global Health – Coalition for Global Hepatitis Elimination (pdf, 466.201 Mb)John WardQ&A and barriers to add |
Session 1.5: Actions taken by patient organisations
| 14:30-15:30 | World Hepatitis Alliance (WHA) (pdf, 1.675 Mb)Cary JamesEuropean Liver Patients’ Association (ELPA) (pdf, 3.072 Mb)Ivana DragojevićLiver Patients International (LPI) (pdf, 0.170 Mb)José WillemseQ&A and barriers to add |
COFFEE break 15:30-16u00
Session 1.6: Role of International organisations (part 3)
| Chairs: Erika Duffell and Sandra Dudareva | |
| 16:00-17:20 | European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (pdf, 1.080 Mb)Thomas Seyler (ONLINE)Correlation Network (pdf, 3.506 Mb)Roberto Pérez GayoInternational Centre for Migration, Health and Development (ICMHD) (pdf, 0.118Mb)Manuel CarballoUNITE (pdf, 9.025 Mb)Ricardo Baptista Leite (ONLINE)Q&A and barriers to add |
Session 1.7: European projects highlighted
| 17:20-18:00 | International projects working toward the elimination goalsCORE “COmmunity REsponse to End Inequalities” (pdf, 0.643 Mb)Oksana PanochenkoBOOST (pdf, 0.867 Mb)Roberto Pérez GayoVH-COMSAVAC (pdf, 7.129 Mb)Camila Picchio (ONLINE)RISE-Vac (mp4, 169.579 Mb)Lara Tavoschi (PRE-RECORDED) |
| 18:00-18:20 | EU initiatives focusing on hepatitis (pdf, 0.953 Mb)Katharina Ossenberg (ONLINE) |
| 18:20-18:40 | Ranking the identified barriers – general discussionOrganisations indicate which barriers they can help to overcome. |
DINNER at 19:30
Thursday 6 April 2023 – Part 2
Session 2.1: Role of International organisations (part 4)
| Chairs: Marcelo Naveira and Françoise Roudot-Thoraval | |
| 08:30-09:10 | Center for Disease Analysis (CDA) (pdf, 2.190 Mb)Devin Razavi-Shearer & Sarah BlachEuropean Society for Clinical Virology (ESCV) (pdf, 1.164 Mb)Xavier López Labrador |
| 09:10-09:30 | European Association for the Study of the Liver (EASL) (pdf, 5.184 Mb)Maria Buti |
| 09:30-10:00 | Associations Collaborating on Hepatitis to Immunise and Eliminate the Viruses in Europe (ACHIEVE) (pdf, 1.765 Mb)Katharina Ossenberg (ONLINE) |
| 10:00-10:20 | Q&A and barriers to add |
COFFEE break 10:20-11:00
Session 2.2: Groups discussions
| Chairs: John Ward | |
| 11:00-12:00 | Ranking the identified barriers – groups discussions Each group discusses how to handle one of the identified barriers, with a focus on the capacity of international organisations and how to work together better to improve the outcome. |
| 12:00-12:30 | Outcome of the groups discussions & general discussion |
LUNCH 12:30-14:00
Session 2.3: Meeting summary by David FitzSimons
| Chairs: Mark Kane and Pierre Van Damme | |
| 14:00-14:40 | Meeting summary (pdf, 0.211 Mb)David FitzSimons |
| 14:40-15:00 | Closing remarks |
Meeting report (375kB, Pdf) by David FitzSimons.